Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Celldex Therapeutics (CLDX) Capital Expenditures (2016 - 2025)

Celldex Therapeutics (CLDX) has 16 years of Capital Expenditures data on record, last reported at $1.3 million in Q4 2025.

  • For Q4 2025, Capital Expenditures rose 69.44% year-over-year to $1.3 million; the TTM value through Dec 2025 reached $2.7 million, up 41.43%, while the annual FY2025 figure was $2.7 million, 41.43% up from the prior year.
  • Capital Expenditures reached $1.3 million in Q4 2025 per CLDX's latest filing, up from $440000.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $1.3 million in Q4 2025 and bottomed at $143000.0 in Q2 2021.
  • Average Capital Expenditures over 5 years is $476400.0, with a median of $425000.0 recorded in 2023.
  • Peak YoY movement for Capital Expenditures: crashed 84.29% in 2021, then surged 370.63% in 2022.
  • A 5-year view of Capital Expenditures shows it stood at $354000.0 in 2021, then plummeted by 33.62% to $235000.0 in 2022, then surged by 183.4% to $666000.0 in 2023, then rose by 13.51% to $756000.0 in 2024, then skyrocketed by 69.44% to $1.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Capital Expenditures were $1.3 million in Q4 2025, $440000.0 in Q3 2025, and $728000.0 in Q2 2025.